FDA grants Type B meeting for Praxis's ulixacaltamide in Q4 2025

Praxis Precision Medicines, Inc.

FDA granted a Type B meeting following review of Essential3 topline results for ulixacaltamide.
Meeting to occur in Q4 2025; pre-NDA meeting request was previously disclosed.
Corporate presentation updated and posted on investors.praxismedicines.com.
No financial results or guidance changes included in this filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.